Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both conditions.

The diabetes and weight loss drug tirzepatide — sold as Mounjaro and Zepbound, respectively — significantly improved heart failure symptoms and related physical limitations in a new study. [1] ...

Key Takeaways Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients with obesity and HFpEF, compared to placebo.

Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification, or cardiovascular death by 38% compared to placebo.

Eli Lilly’s weight loss and diabetes injection tirzepatide—the active ingredient in Zepbound and Mounjaro—could improve symptoms of heart failure in patients with obesity, the company said ...

Eli Lilly's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday. The findings ...

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a ...